U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Adult
Aged
Female
Food-Drug Interactions
Humans
Imidazoles
/ administration & dosage
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging
Neoplasms
/ diagnosis
Protein Kinase Inhibitors
/ administration & dosage
Protein-Tyrosine Kinases
/ antagonists & inhibitors
Proto-Oncogene Proteins
/ antagonists & inhibitors
Pyridazines
/ administration & dosage
Receptor, trkA
/ antagonists & inhibitors
Response Evaluation Criteria in Solid Tumors
Young Adult
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
28
04
2020
revised:
06
06
2020
accepted:
24
06
2020
pubmed:
28
6
2020
medline:
15
12
2021
entrez:
28
6
2020
Statut:
ppublish
Résumé
Taletrectinib (DS-6051b/AB-106) is an oral, tyrosine kinase inhibitor of ROS1 and NTRK with potent preclinical activity against Patients ≥18 years old with neuroendocrine tumors, with tumor-induced pain, or tumors harboring A total of 46 patients were enrolled. Steady-state peak concentration ( Taletrectinib has manageable toxicities at the MTD of 800 mg daily. Preliminary efficacy was observed in patients with crizotinib-refractory
Identifiants
pubmed: 32591465
pii: 1078-0432.CCR-20-1630
doi: 10.1158/1078-0432.CCR-20-1630
doi:
Substances chimiques
Imidazoles
0
NTRK1 protein, human
0
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins
0
Pyridazines
0
Protein-Tyrosine Kinases
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
Receptor, trkA
EC 2.7.10.1
taletrectinib
W4141180YD
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4785-4794Informations de copyright
©2020 American Association for Cancer Research.